Latest California Healthline Stories
Seniors Miss Out On Clinical Trials
Among hurdles: Older adults may have multiple illnesses that could complicate research or they might be unable to manage the commute.
Exclusive: White House Task Force Echoes Pharma Proposals
Documents examined by Kaiser Health News shed light on the workings of the Trump administration’s “Drug Pricing and Innovation Working Group.”
Tweet Revenge: Twitter Erupts As Diabetes Forum Tries To Lock Down Photo Sharing
This year’s American Diabetes Association scientific meeting comes with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
‘How Long Have I Got, Doc?’ Why Many Cancer Patients Don’t Have Answers
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
“¿Cuánto tiempo me queda, doctor?” Por qué muchos pacientes con cáncer no obtienen respuestas
Muchas veces los pacientes con cáncer no reciben respuestas adecuadas a preguntas críticas, entre ellas, la más crucial y universal de todas.
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin Makers’ Profits
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
Former Pharma Reps’ New Mission: To School Docs On High Drug Costs
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
Many COPD Patients Struggle To Pay For Each Medicinal Breath
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
Drug Rebates Reward Industry Players — And Often Hurt Patients
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
Do Best-Selling Drugs That Calm Stomachs Damage Kidneys? The Answer’s Unclear.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.